Literature DB >> 30690057

ROS-generating oxidase NOX1 promotes the self-renewal activity of CD133+ thyroid cancer cells through activation of the Akt signaling.

Cong Wang1, Zhenglin Wang1, Wei Liu1, Zhilong Ai2.   

Abstract

Thyroid cancer results from unregulated expansion of a self-renewing tumor-initiating cell population. The regulatory pathways essential for sustaining the self-renewal of tumor-initiating cells remain largely unknown. Reactive oxygen species (ROS) play a vital role in tumor initiation and progression. In the present study, we found that the level of ROS was higher in CD133 + thyroid cancer cells than in CD133- thyroid cancer cells. The transcriptional level of ROS-generating oxidase NADPH oxidase 1 (NOX1) is high in CD133 + thyroid cancer cells. Activation of STAT3 through phosphorylation is responsible for high activation of NOX1 transcription in CD133 + thyroid cancer cells. Knock down of NOX1 obviously reduced the level of ROS and inhibited the self-renewal activity and tumorigenicity of CD133 + thyroid cancer cells. Furthermore, knock down of NOX1 reduced the activity of PI3K/Akt pathway. Overexpression of active form of Akt rescued the negative effect of NOX1 knockdown on the self-renewal capability of CD133 + thyroid cancer cells. Together, NOX1 promotes the self-renewal property of CD133 + thyroid cancer cells at least partly through activation of the Akt signaling.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Gene expression; STAT3; Tumorigenesis

Mesh:

Substances:

Year:  2019        PMID: 30690057     DOI: 10.1016/j.canlet.2019.01.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Nox1 downregulators: A new class of therapeutics.

Authors:  Matthias Barton; Matthias R Meyer; Eric R Prossnitz
Journal:  Steroids       Date:  2019-09-10       Impact factor: 2.668

2.  Aloin Inhibits the Proliferation and Migration of Gastric Cancer Cells by Regulating NOX2-ROS-Mediated Pro-Survival Signal Pathways.

Authors:  Ziqian Wang; Tuo Tang; Shengnan Wang; Tianyu Cai; Hong Tao; Qing Zhang; Shimei Qi; Zhilin Qi
Journal:  Drug Des Devel Ther       Date:  2020-01-14       Impact factor: 4.162

Review 3.  The double-edged roles of ROS in cancer prevention and therapy.

Authors:  Yawei Wang; Huan Qi; Yu Liu; Chao Duan; Xiaolong Liu; Tian Xia; Di Chen; Hai-Long Piao; Hong-Xu Liu
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 4.  Obesity and Thyroid Cancer Risk: An Update.

Authors:  Fabiana Franchini; Giuseppe Palatucci; Annamaria Colao; Paola Ungaro; Paolo Emidio Macchia; Immacolata Cristina Nettore
Journal:  Int J Environ Res Public Health       Date:  2022-01-20       Impact factor: 3.390

Review 5.  Redox signaling at the crossroads of human health and disease.

Authors:  Jing Zuo; Zhe Zhang; Maochao Luo; Li Zhou; Edouard C Nice; Wei Zhang; Chuang Wang; Canhua Huang
Journal:  MedComm (2020)       Date:  2022-03-31

6.  Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production.

Authors:  Qipeng Wu; Le Li; Chunmeng Miao; Muhammad Hasnat; Lixin Sun; Zhenzhou Jiang; Luyong Zhang
Journal:  Cell Death Dis       Date:  2022-04-13       Impact factor: 8.469

7.  Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma.

Authors:  Ganxun Li; Weiqi Xu; Lu Zhang; Tongtong Liu; Guannan Jin; Jia Song; Jingjing Wu; Yuwei Wang; Weixun Chen; Chuanhan Zhang; Xiaoping Chen; Zeyang Ding; Peng Zhu; Bixiang Zhang
Journal:  EBioMedicine       Date:  2019-09-04       Impact factor: 8.143

8.  Y-27632 Induces Neurite Outgrowth by Activating the NOX1-Mediated AKT and PAK1 Phosphorylation Cascades in PC12 Cells.

Authors:  So Yeong Park; Jeong Mi An; Jeong Taeg Seo; Su Ryeon Seo
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.